EquityZen Growth Technology Fund LLC - Series 2264
Raised
$600K
Investors
41
Min Invest
$9,964
AltStreet Analysis
·Generated from EDGAR primary sources
EquityZen Growth Technology Fund LLC - Series 2264 is a Delaware LLC filed by EquityZen Advisors on 2026-04-02, raising $600K from 41 investors under Rule 506(b) and Section 3(c)(1). The offering has a $10K minimum investment and is part of EquityZen's pre-IPO platform with 1,889 related EDGAR entities. No first sale date was disclosed in this original filing.
This pre-IPO pooled investment vehicle uses the standard 506(b)/3(c)(1) exemption pattern common to retail-accessible secondary market funds. The $10K minimum investment places this offering in the mass-affluent tier, considerably lower than typical institutional pre-IPO vehicles which often require $100K+ minimums.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
EquityZen Advisors LLC
Executive Officer, Director · New York, NY
Philip Haslett
Executive Officer, Director · New York, NY
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
